News
Overall survival was analyzed in real-world patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback